Lonza Group LONN.CH | SWISS SE Exch | Medical-Biomed/Biotech | MktCap CHF40.09B Sales CHF6.70B | Shares 72M Float 68M | EPS Due in 166 Days (e)

41613168111 lonza.com Basel, SWITZERLAND Inc 1897 MGMT owns --
EPS Rank 42

Lonza Group AG is engaged in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment offers small molecule drug substances and intermediates related services. The Cell and Gene segment includes the Cell and Gene Technologies and Bioscience businesses. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland. LESS

ANNUAL - DEC END	2015	2016	2017	2018	2019	2020	2021	2022	2023
EPS CHF	4.91	5.31	10.42	7.51	10.20	11.68	39.65	16.37	8.88
CASH FLOW/SHR CHF	13.13	13.21	12.49	14.51	13.21	15.21	16.38	13.97	19.26
PRETAX MARGIN %	9%	9%	12%	15%	17%	18%	15%	23%	12%
RETURN ON EQUITY %	13%	13%	16%	11%	10%	11%	8%	12%	7%
SALES % CHANGE	4%	9%	10%	22%	-24%	7%	20%	15%	8%
SALES (MIL) CHF	3,803	4,132	4,548	5,542	4,207	4,508	5,409	6,223	6,717
WEEKLY	**14 Jun**	**21 Jun**	**28 Jun**	**5 Jul**	**12 Jul**	**19 Jul**	**26 Jul**	**2 Aug**	**9 Aug**
DATAGRAPH RATING	47	49	48	51	52	56	62	63	63
AVG DAILY VOL (000)	174	170	167	156	153	139	155	157	155
UP DOWN VOLUME	0.6	0.5	0.7	0.7	0.9	0.7	1.2	1.1	1.1
ACCUM/DIST RATING	-25	-30	-31	-20	-8	-13	27	12	-2
RELATIVE STRENGTH	47	42	50	63	69	90	94	93	96
GROUP RANK	8	10	12	9	10	8	8	3	4

2024 Estimate	2025 Estimate
13.52 52%	16.58 23%
Earnings Growth Rate	**Sales Growth Rate**
2022-24 -33% (58 Stability)	15%
2020-24 6% (71 Stability)	11%
COMP RATING 77	SMR RATING C
INV T/O 2.9x 59	
DEBT % 2021-23	26% 18% 31%
TAX RATE 2021-23	11% 16% 17%
BACKLOG 2021-23	-- -- --
R & D 1.60%	BK VAL 4.23x '23
DIV CHF 4.00 (0.7%)	DIV GR RT +7% (5)
BETA 1.39(17.00)	ALPHA 0.03 (0.01)
2023 EMPLOYEES 18,000 (3%)	



FINANCIALS	Sep, 19	Dec, 19	Mar, 20	Jun, 20	Sep, 20	Dec, 20	Mar, 21	Jun, 21	Sep, 21	Dec, 21	Mar, 22	Jun, 22	Sep, 22	Dec, 22	Mar, 23	Jun, 23	Sep, 23	Dec, 23	Mar, 24	Jun, 24
EPS (CHF)		10.20		6.42		5.28		4.29		35.35		6.63		9.73		5.52		3.38		4.78
EPS % CHANGE								-33%		+570%		+55%		-72%		-17%		-65%		-13%
SALES (MIL CHF)		4,207.0		3,074.0		1,434.0		2,542.0		2,867.0		2,982.0		3,241.0		3,078.0		3,639.0		3,057.0
SALES % CHANGE								-17%		+100%		+17%		+13%		+3%		+12%		-1%
EPS % SURPRISE		-2.0%		+8.1%		+0.7%		+44.0%		-29.1%		-0.2%		+3.8%		-8.9%		-8.4%		+38.3%
FUNDS	1,379	1,426	1,495	1,645	1,716	1,803	1,854	1,888	1,935	2,029	2,056	2,172	2,221	2,247	2,255	2,279	2,259	2,103	2,253	2,233
SHARES HELD BY FUNDS	32M	32M	33M	33M	33M	32M	32M	32M	33M	33M	33M	33M	33M	33M	34M	34M	33M	31M	31M	31M

P/E	68
2024 Est.:	41.1
2025 Est.:	33.5
5-yr High:	70
5-yr Low:	11
vs Ind. Avg:	

PANARAY® 2024 WILLIAM O'NEIL + CO. INC.